1-4 of 4
Anil Singhal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Dose Escalation Study of TRU-016, An Anti-CD37 SMIP™ Protein In Relapsed and Refractory CLL

Richard R. Furman, MD, Leslie Andritsos, MD, Ian W. Flinn, MD, PhD, Andres Forero-Torres, MD, Kenneth A. Foon, MD, John M. Pagel, MD, PhD, Anil Singhal, MD, Scott C. Stromatt, MD, John C. Byrd, MD
Journal: Blood
Blood (2010) 116 (21): 56.
https://doi.org/10.1182/blood.V116.21.56.56
Published: 2010
Journal Articles

Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results.

Andrzej J Jakubowiak, William Bensinger, David Siegel, Todd M. Zimmerman, Jan M. Van Tornout, Carol Zhao, Anil Singhal, Kenneth Anderson
Journal: Blood
Blood (2009) 114 (22): 3876.
https://doi.org/10.1182/blood.V114.22.3876.3876
Published: 2009
Journal Articles

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

Sagar Lonial, Ravi Vij, Jean-Luc Harousseau, Thierry Facon, Jonathan Kaufman, Amitabha Mazumder, Philippe Moreau, Xavier Leleu, John Fry, Anil Singhal, Sundar Jagannath
Journal: Blood
Blood (2009) 114 (22): 432.
https://doi.org/10.1182/blood.V114.22.432.432
Published: 2009
Journal Articles

Phase I Study of Elotuzumab (HuLuc63) in Phase I Study of Elotuzumab (HuLuc63) in Relapsed/Refractory Multiple Myeloma

Jeffrey A. Zonder, Seema Singhal, William Bensinger, Ann Mohrbacher, Mohamad A. Hussein, Nikhil C. Munshi, Ingrid Caras, Anil Singhal, Frits van Rhee
Journal: Blood
Blood (2008) 112 (11): 2773.
https://doi.org/10.1182/blood.V112.11.2773.2773
Published: 2008